HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $270

Benzinga Newsdesk www.benzinga.com Positive 81.2%

Neg 0% Neu 0% Pos 81.2%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $260 to $270.